# Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

Source: https://onco.cc/trials/nct04626479/  
OnCo record `nct04626479` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab, Favezelimab, Belzutifan and Lenvatinib in renal cell carcinoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.

## Summary

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) is a phase 1/2 interventional study registered as NCT04626479 by Merck Sharp & Dohme LLC, with 400 participants enrolled, started 2020-12-16 and due to reach its primary completion in 2026-08-21. Interventions recorded: Pembrolizumab, Favezelimab/Pembrolizumab, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab and Vibostolimab/Pembrolizumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04626479
- Phase: 1/2
- Setting: A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03A in First Line Metastatic Participants
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 400

## Sources

- ClinicalTrials.gov NCT04626479: https://clinicaltrials.gov/study/NCT04626479

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Belzutifan](https://onco.cc/drugs/belzutifan/), [Favezelimab](https://onco.cc/drugs/favezelimab/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct04626479.json